ICAD INC: management transactions · United States · SEC (Form 4)

About ICAD INC

iCAD Inc. is a U.S.-based medical technology company listed on the NASDAQ market in the United States. Headquartered in Nashua, New Hampshire, the company has historically focused on technologies used for the early detection and treatment of cancer, with a particularly strong emphasis on breast health. Its profile is that of a specialized, technology-driven medtech company rather than a broad-based healthcare supplier. iCAD’s core business is centered on its ProFound Breast Health Suite, which includes AI-enabled mammography reading support, cancer detection software, short-term breast cancer risk assessment tools, and more recent capabilities related to breast density and breast arterial calcification assessment. The company has also been associated with its Xoft radiation therapy platform, including electronic brachytherapy and intraoperative radiation therapy solutions, although its strategic messaging in recent years has increasingly concentrated on breast imaging and artificial intelligence. In recent disclosures, iCAD has described itself as providing clinically proven AI-powered breast health solutions. From a historical standpoint, iCAD was originally founded in 1984 as Howtek, Inc., and later adopted the iCAD name in 2002. Its corporate headquarters are in Nashua, New Hampshire, reinforcing its operational base in the United States. The company has maintained an international footprint through distributors, commercial partners and a French subsidiary, but its primary commercial exposure remains in North America, serving imaging centers, radiology groups and mammography providers. In competitive terms, iCAD operates in a focused segment of the health-tech market where differentiation depends on clinical performance, workflow integration and peer-reviewed evidence. It competes with imaging software vendors, radiology AI specialists and larger medical device groups. iCAD’s main advantage has been its narrow focus on breast cancer detection and its ability to embed AI into the screening workflow. A major recent development was RadNet’s April 2025 announcement that its DeepHealth subsidiary would acquire iCAD. Subsequent communications indicated shareholder approval efforts and ongoing commercial momentum for ProFound AI, including a partnership with RamSoft. For French-speaking investors, iCAD is therefore best viewed as a NASDAQ-listed U.S. health-tech name whose near-term story is now dominated by its integration into the DeepHealth/RadNet ecosystem.